Understanding the New Recommendations on COVID-19 Boosters

In this Q&A, Eric Rubin, adjunct professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health, editor-in-chief of the New England Journal of Medicine, and temporary voting member of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, discusses the committee’s vote on September 17, 2021 to recommend that people age 65 and older, those at risk of developing severe disease, and people in high-risk occupations receive a booster dose of Pfizer-BioNTech’s COVID-19 vaccine.